Literature DB >> 21553053

The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer.

Esin Koç1, Vildan Caner, Nur Büyükpınarbaşılı, Emre Tepeli, Nilay Sen Türk, G Ozan Çetin, Gülseren Bağcı.   

Abstract

DNA repair plays a key role in prevention of carcinogenesis and one of the most important DNA repair mechanisms is nucleotide excision repair (NER) pathway. This pathway includes a number of genes such as excision repair cross-complementing group 1 (ERCC1) gene which are responsible for the 5' incision of damaged DNA. A reduced DNA repair capacity associated with ERCC1 mRNA level has been observed in lung carcinogenesis. Two single nucleotide polymorphisms (SNPs) in ERCC1 gene, T19007C (rs11615) and C8092A (rs3212986), reportedly predict to affect the mRNA of ERCC1 in non-small cell lung cancer (NSCLC). To examine the role of two common SNPs in ERCC1 gene further, we conducted this study where 80 cases histopatologically diagnosed as NSCLC were genotyped. Genomic DNA was extracted from formalin-fixed, paraffin embedded tissues and two SNPs were analyzed using real-time PCR. The distributions of TT, TC, and CC genotypes of the T19007C SNP were 40, 44 and 16%, respectively. Significantly increased frequency of the patients carrying at least one 19007C allele was observed in early stage compared to advanced stage (P=0.002). And also, the frequency of TC and CC genotypes significantly increased in younger patients compared to older patients (P=0.035). Regarding C8092A SNP, the distribution of CC, CA, and AA genotypes was 38, 51 and 11%, respectively. There was no significant difference in the genotype distribution between C8092A SNP and clinicopathological parameters. This study indicated that harboring at least one 19007C allele may have protective effect in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553053     DOI: 10.1007/s11033-011-0748-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  30 in total

1.  XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.

Authors:  Michele Cummings; Karen Higginbottom; Claire J McGurk; Oscar Gee-Wang Wong; Beate Köberle; R Timothy D Oliver; John R Masters
Journal:  Biochem Pharmacol       Date:  2006-05-04       Impact factor: 5.858

Review 2.  Pathology of hereditary breast cancer.

Authors:  Leonard Da Silva; Sunil R Lakhani
Journal:  Mod Pathol       Date:  2010-05       Impact factor: 7.842

3.  High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.

Authors:  Cathie Garnis; William W Lockwood; Emily Vucic; Yong Ge; Luc Girard; John D Minna; Adi F Gazdar; Stephen Lam; Calum MacAulay; Wan L Lam
Journal:  Int J Cancer       Date:  2006-03-15       Impact factor: 7.396

4.  Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Authors:  J J Yu; K B Lee; C Mu; Q Li; T V Abernathy; F Bostick-Bruton; E Reed
Journal:  Int J Oncol       Date:  2000-03       Impact factor: 5.650

5.  Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

Authors:  D Isla; C Sarries; R Rosell; G Alonso; M Domine; M Taron; G Lopez-Vivanco; C Camps; M Botia; L Nuñez; M Sanchez-Ronco; J J Sanchez; M Lopez-Brea; I Barneto; A Paredes; B Medina; A Artal; P Lianes
Journal:  Ann Oncol       Date:  2004-08       Impact factor: 32.976

Review 6.  Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitrios Bafaloukos; Paris Kosmidis; Samuel Murray
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

7.  Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.

Authors:  Tomoyoshi Takenaka; Tokujiro Yano; Chikako Kiyohara; Naoko Miura; Hidenori Kouso; Taro Ohba; Takuro Kometani; Fumihiro Shoji; Ichiro Yoshino; Yoshihiko Maehara
Journal:  Lung Cancer       Date:  2010-01       Impact factor: 5.705

8.  DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

Authors:  Aristea Kalikaki; Maria Kanaki; Helen Vassalou; John Souglakos; Alexandra Voutsina; Vassilis Georgoulias; Dimitris Mavroudis
Journal:  Clin Lung Cancer       Date:  2009-03       Impact factor: 4.785

Review 9.  Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis.

Authors:  Chikako Kiyohara; Kouichi Yoshimasu
Journal:  Int J Med Sci       Date:  2007-02-01       Impact factor: 3.738

10.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

Authors:  A Kalikaki; A Koutsopoulos; M Trypaki; J Souglakos; E Stathopoulos; V Georgoulias; D Mavroudis; A Voutsina
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

View more
  3 in total

Review 1.  Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.

Authors:  Ning Tang; Dan Lyu; Yan Zhang; Haiping Liu
Journal:  BMC Womens Health       Date:  2017-06-17       Impact factor: 2.809

2.  Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk.

Authors:  Chia-Wen Tsai; Wen-Shin Chang; Te-Chun Shen; Chen-Hsien Su; Hwei-Chung Wang; Liang-Chih Liu; Da-Tian Bau
Journal:  PLoS One       Date:  2018-08-10       Impact factor: 3.752

3.  Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients.

Authors:  Marcin Nicoś; Anna Rolska-Kopińska; Paweł Krawczyk; Anna Grenda; Aleksandra Bożyk; Michał Szczyrek; Janusz Milanowski
Journal:  Arch Med Sci       Date:  2020-01-23       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.